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Graft-versus-host disease (GVHD) is a donor T cell driven response against host tissue that can complicate
allogeneic hematopoietic stem cell transplantation (HSCT). During acute GVHD, endogenous adjuvants such
as uric acid are released by damaged host tissue, activating alloreactive donor T cells. A phase I study was
conducted at the Massachusetts General Hospital between 2007 and 2010 to test the hypothesis that
reduction of uric acid levels during allogeneic HSCT can modulate the development of acute GVHD. Twenty-
one patients with hematologic malignancies in complete remission undergoing myeloablative peripheral
blood HSCT received recombinant urate oxidase at .20 mg/kg for 5 consecutive days during conditioning.
Results were compared with all patients who underwent allogeneic HSCT at our institution during the same
time period who met the same inclusion and exclusion criteria but were not enrolled in the study. The only
major adverse event was a case of hemolytic anemia in a patient who had glucose-6-phosphate dehydro-
genase deﬁciency. Primary outcome was the cumulative incidence of grades II to IV acute GVHD, which was
signiﬁcantly decreased in the treatment group in the intention-to-treat analysis (57% [12/21] versus 24%
[5/21], P ¼ .036) and in the per-protocol analysis (P ¼ .017). Patients who developed acute GVHD had a higher
level of serum uric acid during the pretransplantation period compared with those who did not (P < .001).
There was no difference in disease-free or overall survival. Our study suggests that urate oxidase can be safely
administered during myeloablative conditioning and may reduce the incidence of acute GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) offers the best chance to cure many hematologic
malignancies and serves to both rescue the recipient bone
marrow after conditioning and provide adoptive immuno-
therapy against residual tumor cells. Although enabling a
graft-versus-tumor effect, allogeneic HSCT can also facilitate
the development of graft-versus-host disease (GVHD), a
donor T celledriven immunologic response against healthy
host tissue that can cause signiﬁcantmorbidity andmortality
[1]. The risk of acute GVHD (aGVHD), which is often epide-
miologically deﬁned as disease occurring within the ﬁrst 100
days of transplantation [2], has been estimated to range from
20% to 60%, depending on factors such as intensity of con-
ditioning, type of graft, GVHD prophylaxis regimen, and
varying degrees of donor parity, sex matching, and recipient
age [3,4].
Molecular insight into the pathogenesis of aGVHD is
critical toward the development of novel strategies toedgments on page 734.
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nism of GVHD is complex and is represented by a positive
feedback loop culminating in T cellemediated destruction of
host tissue. In the acute setting, the initiation of GVHD is
thought to involve the stimulation of antigen presenting cells
(APCs) through exposure of the immune system to endoge-
nous “danger signals” from dying cells, which can result from
the cytotoxic effects of conditioning regimens, or to
pathogen-associated molecular patterns from translocation
of gut bacteria [2]. Signaling through APC costimulatory
molecules coupled with antigen presentation subsequently
induce the expansion of alloreactive donor T cells that
recognize mismatched minor histocompatibility complexes
andMHCs, leading to T celleinduced apoptosis of host tissue,
which causes further release of endogenous adjuvants that
aggravates the cycle [1,5].
In this study we wanted to examine the feasibility and
potential effect of suppressing the activation of APCs and
thereby break the GVHD cycle by targeting an important
endogenous “danger signal.” It has long been known that
even in the absence of exposure to microbial products, im-
mune stimulation can occur when dying cells release certain
danger signals that act as endogenous adjuvants. However,
only recently has a speciﬁc soluble factor been identiﬁed to
directly mediate this process. By isolating cytosol from dyingTransplantation.
Table 1
Baseline Characteristics between Rasburicase and Control Groups
Rasburicase
Group
N ¼ 21
Control
Group
N ¼ 21
Mean age, yr (range) 42.9 (20-59) 45 (21-55)
Male 14 (67) 9 (43)
Disease
Acute myelogenous leukemia 14 (67) 13 (62)
Acute lymphoblastic leukemia 5 (24) 4 (19)
Myelodysplastic syndrome d 1 (5)
Non-Hodgkin lymphoma d 2 (10)
Myeloproliferative disease 2 (10) d
Chronic myelogenous leukemia d 1 (5)
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activity, Shi et al. [6] identiﬁed uric acid as one such critical
factor released from injured cells. When co-injected with
antigen in vivo, puriﬁed uric acid signiﬁcantly enhanced
CD8þ T cell response in splenocytes of mice, whereas elim-
ination of the uric acid through the use of allopurinol or
uricase inhibited activation of cytotoxic T lymphocytes [6].
They also demonstrated that in vitro exposure of bone
marrowederived dendritic cells to uric acid can induce up-
regulation of costimulatory molecules CD80 and CD86.
Other studies have further demonstrated the potential of
suppressing uric acid to blunt APC activation and T cell
response against foreign antigens, in 1 case using tumor
xenograft models in mice [7] and in another by using a
transgenic system expressing exogenous antigens [8].
Taken in the context of our current understanding of
aGVHD, these preclinical results suggest that lowering uric
acid levels during the conditioning period before trans-
plantation may suppress the activation of host APCs and
therefore alter the course of aGVHD. We sought to test this
hypothesis through the administration of rasburicase (Elitek/
Fasturtec; Sanoﬁ, Paris, France), a recombinant urate oxidase
enzyme that catalyzes the oxidation of uric acid into allan-
toin, an inactive and soluble metabolite. Rasburicase has
been shown in multiple clinical trials conducted in cancer
patients to be greater than 98% effective at reducing hyper-
uricemia [9-11]. The safety proﬁle has been well established
in adults at a dose up to .20 mg/kg/day for 5 to 7 consecutive
days with minimal side effects except for rare instances of
hemolytic anemia and methemoglobinemia, which have
occurred in patients with glucose-6-phosphate dehydroge-
nase deﬁciency [9]. The use of rasburicase as a potential
therapy to prevent aGVHD has not been studied thus far.
Based on these observations, we developed a phase I
clinical trial that served as both a feasibility study for using
rasburicase in the setting of bone marrow transplantation
and to preliminarily test its ability to reduce the incidence of
aGVHD among patients undergoing myeloablative allogeneic
HSCT. We compared results to matched control subjects
obtained from chart record review including all patients in
the same time period who were not in the study but who
were deemed eligible based on inclusion and exclusion
criteria.Transplant characteristics
Mean engraftment time (range) 15 (13-28) 15 (14-29)
First transplant 21 (100) 19 (90)
MRD 16 (76) 13 (62)
Cyclosporine þ methotrexate 14 (86) 11 (85)
Tacrolimus þ methotrexate 2 (14) 2 (15)
MUD 5 (24) 8 (38)
Tacrolimus þ methotrexate þ ATG 4 (80) 8 (80)
Tacrolimus þ methotrexate 1 (20) 2 (20)
Disease status at time of transplant
Complete remission 20 (95) 21 (100)
Conditioning protocol
Busulfan þ cyclophosphamide/
ﬂudarabine*
14 (67) 16 (76)
TBI þ cyclophosphamide 7 (33) 5 (24)
ATG indicates antithymocyte globulin; TBI, total body irradiation.
Values are total number of cases, with percents in parentheses, unless
otherwise noted. All parameters measured were similar between the 2
groups. Parameters (P): age (P¼ .561), sex (P¼ .215), disease type (P¼ .292),
engraftment time (P ¼ .977), % ﬁrst transplant (P ¼ 1.00), type of donor (P ¼
.506), MRD GVHD prophylaxis (P ¼ 1.000), MUD GVHD prophylaxis (P ¼
1.000), disease status at time of transplant (P¼ 1.000), conditioning protocol
(P ¼ .734).
* Two patients in the rasburicase group received busulfan and ﬂudarabine
for the conditioning protocol and the remainder of the patients in both
groups received busulfan and cyclophosphamide.METHODS
Institutional review board approval by the Dana-Farber Cancer Institute/
Partners Cancer Care was obtained on April 17, 2007. Twenty-one patients
with hematologic malignancies in complete remission who received mye-
loablative preparative regimens followed by granulocyte colony-stimulating
factoremobilized HLA-matched peripheral blood HSCT were enrolled in a
pilot trial between 2007 and 2010 at theMassachusetts General Hospital. All
transplants were derived from 8/8 HLA allele (A, B, C, DRB1) matched related
or 8/8 HLA allele matched unrelated donors.
Conditioning regimens were chosen before study enrollment and based
on individual investigator’s discretion. These included myeloablative doses
of either (1) busulfan (3.2 mg/kg/day from day e7 to day e4) and cyclo-
phosphamide (60 mg/kg/day on day e3 and day e2), (2) busulfan (3.2 mg/
kg/day from day e6 to day e3) and ﬂudarabine (40 mg/m2/day from day e6
to day e3), or (3) cyclophosphamide (60 mg/kg/day on day e3 and day e2)
and total body irradiation (13.2 Gy over 8 fractions from day e7 to day e4).
GVHD prophylaxis was also chosen based on individual physician’s discre-
tion and consisted of cyclosporine or tacrolimus in addition to methotrexate
for matched related donor (MRD) transplants and tacrolimus, methotrexate,
with or without rabbit antithymocyte globulin (1.5 mg/kg/day on days e3,
e2, ande1), for matched unrelated donor (MUD) transplants. In the absence
of GVHD, tapering was begun at 100 days post-transplant and discontinued
at day 180. Rasburicase was administered intravenously for 5 consecutive
days beginning on the ﬁrst day of conditioning at a dose of .20mg/kg over 30
minutes.Outcomes were compared with all patients in complete remission un-
dergoing myeloablative allogeneic HSCT between 2007 and 2010 at this
institution but who did not enroll in the trial, identiﬁed via medical records
chart review. Control patients received 300 mg allopurinol daily from the
ﬁrst day of conditioning to day e1 as part of the institutional guidelines.
Adverse events were classiﬁed using the Common Terminology Criteria for
Adverse Events (CTCAE v4.0, National Institutes of Health). The primary
study endpoints included feasibility and cumulative incidence of grades II to
IV aGVHD as deﬁned by Thomas et al. [12].
Differences in disease type, gender, percentage of ﬁrst transplant, donor
type, aGVHD prophylaxis, conditioning regimen, and incidence of chronic
GVHD (cGVHD) were evaluated using Fisher’s exact test or chi-square test.
Differences in age, engraftment time, average uric acid levels, and time to
aGVHD were evaluated using the Wilcoxon test. Cumulative incidence of
aGVHD grades II to IV was estimated in the presence of death as a competing
risk, and the difference between curves was compared using Gray’s test [13].
Severity of cGVHD was classiﬁed according to Filipovich et al. [14]. Overall
survival and progression-free survival were calculated using the method of
Kaplan and Meier. Statistical analysis was performed using R Statistical
Software (version 2.15.2; Foundation for Statistical Computing, Vienna,
Austria).RESULTS
Twenty-one patients were included in both the rasburi-
case and control groups. Baseline characteristics collected for
the remaining patients in each group included age, gender,
type of disease, disease status at time of transplant, trans-
plant type, conditioning regimen, and number of prior
transplants. Therewere no statistical differences in any of the
baseline characteristics between the 2 groups (Table 1).
Engraftment was achieved in all patients, and the median
time to combined neutrophil (.5  109/L) and platelet
Figure 2. Breakdown of aGVHD by grade in control versus rasburicase groups.
All transplant types (control, 12/21; grade II, 5; grade III, 3; grade IV, 4 versus
rasburicase, 5/21; grade II, 2; grade III, 2; grade IV, 1), MRD (control, 7/13;
grade II, 4; grade IV, 3 versus rasburicase 4/16; grade II, 2; grade III, 1; grade IV,
1), and MUD (control, 5/8; grade II, 1; grade III, 3; grade IV, 1 versus rasburi-
case, 1/5; grade III, 1).
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most common type of adverse events in the rasburicase
group was mucositis, nausea, diarrhea, and vomiting,
although the incidence of these events were no different
from that seen in the control group and likely reﬂect the side
effect proﬁle from the conditioning regimen (Supplemental
Table 1). The only grades III or IV adverse event attribut-
able to rasburicase was intravascular hemolysis in a patient
that occurred after 2 doses of rasburicase. This patient
recovered and was later found to have glucose-6-phosphate
dehydrogenase deﬁciency, a condition known to cause a
predisposition to rasburicase-induced hemolysis from
oxidative stress [9]. The patient did not receive any further
doses of rasburicase and was removed from the per-protocol
analysis. Another patient in the rasburicase group experi-
enced tongue numbness without swelling on day e1 of
transplant that resolved in 2 dayswith no interference in oral
intake.
Comparison of serum uric acid levels showed that pa-
tients who received rasburicase achieved a signiﬁcantly
lower level of uric acid from day e7 to day þ1 of trans-
plantation compared with the control group (Figure 1), with
most patients in the treatment group achieving a serum uric
acid level of .0 mg/dL after 1 day of treatment. Of note, pa-
tients who were not part of the study received allopurinol
per institutional guidelines, which accounts for the decrease
in uric acid levels in the control group. aGVHD occurred in 12
of 21 patients in the control group (57%; grade II, 5; grade III,
3; and grade IV, 4) and in 5 of 21 patients in the treatment
group (24%; grade II, 2; grade III, 2; and grade IV,1) (Figure 2).
Involvement by organ system is noted in Supplemental
Table 2.
The cumulative incidence of grades II to IV aGVHD was
higher in the control group compared with the rasburicase
group, reaching statistical signiﬁcance in the intention-to-
treat analysis (P ¼ .036) and per-protocol analysis (P ¼
.017), which excluded the patient who received only 2 doses
of rasburicase (Figure 3A,B). Of note, 2 patients in the control
group and 1 patient in the rasburicase group experiencedFigure 1. Serum uric acid levels pre- and post-transplant in control (triangle)
versus rasburicase (circle) groups from day e7 to day 6. The rasburicase group
had signiﬁcantly higher levels of serum uric acid (P < .050) than the control
group for each day from day e7 to day 1.aGVHD after donor lymphocyte infusions for evidence of
relapsed disease at days 155, 308, and 189, respectively.
When these patients were removed from the aGVHD group
based on competing risk, statistical signiﬁcance was main-
tained in the per-protocol analysis (P ¼ .030) and trended
toward signiﬁcance in the intention-to-treat analysis (P ¼
.064). Subgroup analysis by transplant type suggested thatFigure 3. (A) Cumulative incidence of grades II to IV aGVHD in matched
control subjects versus rasburicase treated patients, intention-to-treat (P ¼
.036). (B) Cumulative incidence of grades II to IV aGVHD in matched control
subjects versus rasburicase treated patients, per-protocol (P ¼ .017).
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transplants (63% versus 20% developed aGVHD) compared
with MRD transplants (54% versus 25%), although our study
was not sufﬁciently powered to detect statistical difference
between these categories.
There was no difference in the time to aGVHD onset be-
tween the 2 groups (mean control, 55.0 days, versus ras-
buricase, 48.0 days, P ¼ .531). There was also no difference in
the incidence of cGVHD (control, 12/21, versus rasburicase,
12/21) or the severity of cGVHD (control, 5 mild and 7
moderate-severe, versus rasburicase, 8 mild and 4moderate-
severe, P ¼ .414), although there was a trend toward milder
cGVHD in the rasburicase group. Two cases of cGVHD in the
control group and 2 cases in the rasburicase group were
deemed as possible overlap syndrome. In the control group,
there was 1 case of mild cutaneous GVHD at day 152 of
transplant and moderate hepatic GVHD at day 202 of trans-
plant. In the rasburicase group, there were 2 cases of mild
cutaneous GVHD that occurred on transplant days 122 and
155. Of note, if these overlap syndromes were counted as
aGVHD, only the case of moderate hepatic GVHDwould have
been categorized in the grades II to IV category.
There was no difference in progression-free or overall
survival between the 2 groups. Nine deaths that occurred in
the control group included 7 cases of relapsed disease, 1 case
of infection associated with increased immunosuppression
from aGVHD ﬂare at transplant day 177, and 1 case of res-
piratory failure thought secondary to pneumonia and ﬁbrotic
lung disease at transplant day 60. Nine deaths also occurred
in the rasburicase group, which included 7 cases of relapsed
disease, 1 case of H1N1 inﬂuenza at transplant day 510, and 1
case of metapneumovirus at transplant day 53.
We also determined whether serum uric acid level is
associated with development of aGVHD. Of all patients
included in the study, those who developed grades II to IV
aGVHD had a signiﬁcantly higher average daily level of serum
uric acid during the pretransplant period compared with
those who did not (P < .001) (Figure 4A). Subgroup analysis
suggested a similar pattern for patients receiving MRD
transplants (Figure 4B) and MUD transplants (Figure 4C).Figure 4. Serum uric acid levels measured from day e7 to day 6 of transplant for a
transplant (day 0 to day 6) serum uric acid levels for all patients in the study who d
(circles) were as follows: pre, 2.08 mg/dL versus 1.12 mg/dL, P < .001; and post, 2.50
(pre, 1.97 mg/dL versus .93 mg/dL, P < .001; post, 2.66 mg/dL versus 2.55 mg/dL, P ¼ .5
versus 1.60 mg/dL, P ¼ .078; post, 2.25 mg/dL versus 1.84 mg/dL, P ¼ .195).DISCUSSION
Our results leave many questions unanswered and have
several limitations. First, this is a nonrandomized, single-
center study, and thus patient selection in the experi-
mental group may be biased toward positive outcome
despite our best efforts at matching control subjects. We also
acknowledge that although the timing and duration of ras-
buricase administration was based on hypotheses generated
from preclinical data as well as data on its safety and efﬁcacy
[10,11], we have not established the optimal duration of
rasburicase administration. Extending the administration of
rasburicase may increase its effectiveness because we
demonstrated that uric acid levels rise immediately after
cessation of treatment. However, it is impossible to deter-
mine in the current study if the elevation of uric acid during
this period is simply a marker of increased inﬂammation or if
it plays a causative role in the disease development. Another
limitation of our study stems from our methodology in
measuring uric acid. Serum uric acid may not accurately
reﬂect tissue uric acid levels, which is likely more physio-
logically relevant and thus could limit our ability to make a
more robust association between uric acid levels and GVHD
outcome.
It also remains unclear whether prolonged suppression of
uric acid could diminish the graft-versus-tumor response.
The lack of difference in progression-free survival between
the control and treatment group suggests that, at least with
this brief administration, there does not seem to be a risk of
dampening a graft-versus-tumor effect. Notably, our control
patients all received allopurinol before transplantation as a
part of institutional guidelines, which is not the standard
across all transplant centers and which results in a decrease
in serum uric acid levels as well, albeit to a signiﬁcantly
lesser degree than uricolytic agents. However, we do not
believe this decreases the validity of our study for 2 reasons.
First, the incidence of aGVHD in the control group is similar
to that reported in literature, suggesting that the control
group provides a reasonable basis for comparison. Second, if
decreasing uric acid levels do have a protective effect, then
the results we see compared with the control group may bell study patients. (A) The average pretransplant (day e7 to day e1) and post-
eveloped grades II to IV aGVHD (triangles) compared with those who did not
versus 2.36, P ¼ .405. (B) Average serum uric acid levels for MRD patients only
58). (C) Average serum uric acid levels for MUD patients only (pre, 2.25 mg/dL
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thus have a higher baseline of serum uric acid.
In summary, our data so far provide evidence that the use
of rasburicase to lower serum uric acid levels has the po-
tential to reduce the incidence of aGVHD in a safe manner in
patients without glucose-6-phosphate dehydrogenase deﬁ-
ciency. Although not designed as our primary outcome, the
larger reduction of GVHD seen in the MUD transplants
compared with the MRD transplants is another piece of ev-
idence that supports our hypothesis, because it is reasonable
to hypothesize that the higher degree of unwanted T cell
activation caused by more potential antigenic mismatches in
the MUD subgroup would beneﬁt more from suppression of
uric acid levels. These observations are concordant with the
underlying mechanistic framework of aGVHD: the initial
cytotoxicity induced by the transplant protocol releases uric
acid and other pro-inﬂammatory soluble factors that
potentiate host APCs that then lead to increased CD8þ T cell
activity and tissue damage. Based on these data, further work
in mouse models is necessary to determine the precise
mechanism behind uric acid suppression in aGVHD and to
determine the optimal timing and administration of urico-
lytic agents. A prospective, randomized study is also a logical
follow-up to assess the efﬁcacy of uric acid suppression on
aGVHD.
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